TNIB Stock UPDATES Tni Biotech Inc (TNIB) 0.3700 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tni Biotech Inc (TNIB) 0.3700 $TNIB

TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
PR Newswire - Mon Jul 28, 8:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company" , a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014.

TNI BioTech, Inc. Establishes New Record Date for Spin-Off Stock Dividend of Cytocom, Inc. Shares
PR Newswire - Mon Jul 14, 2:17PM CDT
TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company" , a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB.

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa - CORRECTION
PR Newswire - Wed Jun 25, 10:17AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa
PR Newswire - Wed Jun 25, 7:35AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" is pleased to announce that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Cancels Proposed Reverse Split of its Common Stock
PR Newswire - Tue Jun 24, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, announced today that its Board of Directors had passed a resolution cancelling the previously announced 9:10 reverse split of its common stock, as per the 14A Information Statement filed with the Securities and Exchange Commission on June 18, 2014, and accordingly will notify all appropriate regulatory authorities that the reverse split is withdrawn.

TNI BioTech, Inc. Files Schedule 14A and Announces Annual Meeting
PR Newswire - Wed Jun 18, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" announced today that it will hold its 2014 Annual Meeting ("Annual Meeting" of Stockholders on August 25, 2014. The Company has fixed the close of business on July 11, 2014 as the record date for determining shareholders entitled to notice of, and to vote at, the Annual Meeting. At the Annual Meeting, stockholders will be asked to elect eight directors to serve until the 2015 annual meeting of stockholders and until their successors have been elected and qualified.

TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement" on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang" .

TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.

The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG" a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.

TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC" that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.

TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:

TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.

TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.

TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.

FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK® Phase III Study Design
ACCESSWIRE - Tue Jul 09, 8:24AM CDT
Bethesda, MD (eTeligis via ACCESSWIRE) - July 8, 2013 - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK® in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.

FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK[R] Phase III Study Design
ACCESSWIRE - Tue Jul 09, 7:20AM CDT
Bethesda, MD, July 9, 2013 - (eTeligis via Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK[R] in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.

TNI BioTech, Inc., Concludes Type C Meeting at the FDA
ACCESSWIRE - Mon Jul 01, 9:26AM CDT
BETHESDA, Md - (Eteligis via Accesswire ) -- TNI BioTech, Inc. ("TNIB", the "Company" (OTCQB: TNIB) announced today that it has a Type C Meeting with the FDA in Washington, D.C., to review the Company's Development Program for its Phase III Drug Candidate, Naltrexone HCL [Low Dose Naltrexone (LDN) IRT-103



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Dyne Therapeutics Faces Legal Inquiry Amid FDA Approval Delays

Updated Category News Views 189

Understanding the Investigation Surrounding Dyne Therapeutics Recently, Pomerantz LLP, a recognized law firm, initiated an investigation on behalf of investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). The focus of this inquiry is on whether Dyne and its executives have participated in unlawful business practices, including securities fraud. These claims arise amidst...

Continue Reading
ThermAI Secures Major Investment from Tech Visionary Daniel Keller

Updated Category News Views 334

ThermAI's Innovative Breakthrough in Heat Recovery Technology ThermAI, a groundbreaking decentralised compute and heat-recovery protocol, has recently secured a strategic investment from Daniel Keller, a prominent figure in the tech industry known for co-founding Flux and playing a pivotal role in architecting Zelcore. This partnership is set to expedite ThermAI's...

Continue Reading
CAPTRUST Expands Reach with Carolinas Investment Consulting

Updated Category News Views 119

CAPTRUST Welcomes Carolinas Investment Consulting CAPTRUST Financial Advisors, known for their commitment to excellent service in the financial advisory realm, is embracing a new chapter with the addition of Carolinas Investment Consulting (CIC). This collaboration aims to deliver enhanced investment consulting and financial planning services to an even broader clientele....

Continue Reading
Essential Vehicle Preparations for College Students

Updated Category News Views 141

Get Your Car Ready for College Mercury Insurance Provides a Checklist to Make Sure You're Prepared As the academic year approaches, it's that time when students gear up to head back to campus. Whether you're a parent assisting your child or a student planning to drive yourself, it's crucial to ensure that your vehicle is ready for the journey ahead. Understanding this...

Continue Reading
Cineverse Unveils cineSearch: Revolutionizing Streaming Search

Updated Category News Views 406

Cineverse Introduces cineSearch for Enhanced Content Discovery AI-Powered cineSearch Unlocks Personalized Content Recommendations Across Leading Streaming Platforms Cineverse Corp. (NASDAQ: CNVS), an innovative streaming technology and entertainment company, is excited to announce the public preview of cineSearch, its groundbreaking AI-driven content discovery tool....

Continue Reading